Laurus Labs

Stocks to buy: MCX has formed a bullish candle, reclaimed the 50-DEMA and started making higher highs, indicating renewed buying interest, explains Chandan Taparia of Motilal Oswal.

FPIs increased stake in Laurus to 30.8% in the September 2026 quarter from 28% at the end of June 2026 quarter, shareholding data shows.

Laurus Labs Q2 outlook: On the EBITDA front, analysts at Kotak Institutional Equities build in 67% YoY growth to ₹680 crore in Q2FY27 with EBITDA margin expansion of 680 bps to 31.2%.

Divi's Laboratories remains the top pick for most brokerages in this segment, even as valuations turn rich after the sharp rally

The BSE Healthcare index rallied over 1% in Monday's trade. Thus far in the financial year 2026-27, it outperformed the market by soaring 25%, against a near 4% rise in the BSE Sensex.

Among the new additions, Laurus Labs saw its market-cap rise 92 per cent to ₹1.03 trillion from ₹53,546 crore as of March 30, 2026

The MSCI Standard Index will see four additions, Adani Energy Solutions, Billionbrains Garage Ventures, Laurus Labs, and Lenskart Solutions.

India's CRDMO sector growth rebounded to 19% YoY in Q1FY27 versus just 9% YoY in the March 2026 quarter, marking the highest growth level since the December 2024 quarter, notes Jefferies.

MSCI's August review adds four Indian companies and removes three, with India's index weight rising marginally to 11.9 per cent and constituents increasing to 166

In the past month, Laurus Labs outperformed the market by surging 22 per cent, as compared to 2.1 per cent rise in the Nifty Midcap 50 index.

Motilal Oswal's Chandan Taparia recommends Hero MotoCorp, Siemens, and Laurus Labs as technical buy ideas, citing bullish chart patterns, breakout formations, and strong sectoral momentum.

The BSE Healthcare hit a new high of 51,108 on Friday, rallying 3.7% in July. The index has surged 22% since April 2026.

Among others, Manappuram Finance, Marico, Radico Khaitan, Redington, Welspun Corp, Laurus Labs and Sai Life Sciences also touched respective all-time highs in trade on Thursday.

Laurus Labs quoted higher for the fourth straight day, surging 15% in this period after delivering record quarterly revenue with expanded profitability and continued portfolio transformation.

The stock price of Laurus Labs hit a new high of ₹1,662.45 in intra-day deals on Monday; the stock has zoomed 176% in the past 14 months from levels of ₹601.75 on May 27, 2025.

Laurus Labs on Friday reported a 124.7% YoY surge in Q1 consolidated net profit at ₹361.99 crore, backed by 28.8% growth in total income. The stock has nearly doubled in the last one year.

Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.

Sustained clinical and commercial contracting across technologies and sites driving good growth outlook for CDMO business, the company said.

In the past seven trading days, the Nifty Pharma index outperformed the market by soaring 5.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.

Analysts said that a combination of defensive buying, strong earnings visibility, export tailwinds, and sector rotation is driving the rally in pharma stocks.